



# Synthesis of Isoxazole and 1,2,3-Triazole Isoindole Derivatives via Silver- and Copper-Catalyzed 1,3-Dipolar Cycloaddition Reaction

M.M. Rammah, W. Gati, H. Mtiraoui, M. El Baker Rammah, K. Ciamala, M. Knorr, Y. Rousselin, M.M. Kubicki

## ► To cite this version:

M.M. Rammah, W. Gati, H. Mtiraoui, M. El Baker Rammah, K. Ciamala, et al.. Synthesis of Isoxazole and 1,2,3-Triazole Isoindole Derivatives via Silver- and Copper-Catalyzed 1,3-Dipolar Cycloaddition Reaction. *Molecules*, 2016, 21 (3), pp.307. 10.3390/molecules21030307 . hal-01292717

**HAL Id: hal-01292717**

**<https://hal.science/hal-01292717>**

Submitted on 18 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NoDerivatives 4.0 International License

## Article

# Synthesis of Isoxazole and 1,2,3-Triazole Isoindole Derivatives via Silver- and Copper-Catalyzed 1,3-Dipolar Cycloaddition Reactions <sup>†</sup>

Mohamed Mehdi Rammah <sup>1,\*</sup>, Wafa Gati <sup>1</sup>, Hasan Mtiraoui <sup>1</sup>, Mohamed El Baker Rammah <sup>1</sup>, Kabula Ciamala <sup>2</sup>, Michael Knorr <sup>2,\*</sup>, Yoann Rousselin <sup>3</sup> and Marek M. Kubicki <sup>3</sup>

<sup>1</sup> Laboratory of Heterocyclic Chemistry Natural Products and Reactivity/LCHPNR, Department of Chemistry, Faculty of Science, University of Monastir, 5000 Monastir, Tunisia; wafa.gati@yahoo.fr (W.G.); mtiraoui1hasan@gmail.com (H.M.); rammahmbaker@gmail.com (M.E.B.R.)

<sup>2</sup> Institut UTINAM—UMR CNRS 6213, Université de Franche-Comté, 16 Route de Gray, 25030 Besançon, France; ciamalak@yahoo.fr

<sup>3</sup> Institut de Chimie Moléculaire—UMR CNRS 6302, Université de Bourgogne, 21078 Dijon, France; Yoann.Rousselin@u-bourgogne.fr (Y.R.); Marek.Kubicki@u-bourgogne.fr (M.M.K.)

\* Correspondence: mehdiram@yahoo.fr (M.M.R.); michael.knorr@univ-fcomte.fr (M.K.); Tel.: +216-98-31-32-38 (M.M.R.); +33-3-8166-6270 (M.K.)

<sup>†</sup> Dedicated to the memory of Professor Bernard Laude, deceased in 2015.

Academic Editor: Sonia A. C. Carabineiro

Received: 16 January 2016 ; Accepted: 26 February 2016 ; Published: 4 March 2016

**Abstract:** The CuI- or Ag<sub>2</sub>CO<sub>3</sub>-catalyzed [3+2] cycloaddition of propargyl-substituted dihydroisoindolin-1-one (**3**) with aryl nitrile oxides **1a–d** (Ar = Ph, *p*-MeC<sub>6</sub>H<sub>4</sub>, *p*-MeOC<sub>6</sub>H<sub>4</sub>, *p*-ClC<sub>6</sub>H<sub>4</sub>) produces in good yields novel 3,5-disubstituted isoxazoles **4** of the ethyl-2-benzyl-3-oxo-1-((3-arylisoxazol-5yl)methyl)-2,3-dihydro-1*H*-isoindole-1-carboxylate type. With aryl azides **2a–d** (Ar = Ph, *p*-MeC<sub>6</sub>H<sub>4</sub>, *p*-OMeC<sub>6</sub>H<sub>4</sub>, *p*-ClC<sub>6</sub>H<sub>4</sub>), a series of 1,4-disubstituted 1,2,3-triazoles **6** (ethyl-2-benzyl-3-oxo-1-((1-aryl-1*H*-1,2,3-triazol-4-yl)methyl)-2,3-dihydro-1*H*-isoindole-1-carboxylates) was obtained. The reactions proceed in a regioselective manner affording exclusively racemic adducts **4** and **6**. Compared to the uncatalyzed cycloaddition, the yields are significantly improved in the presence of CuI as catalyst, without alteration of the selectivity. The regio- and stereochemistry of the cycloadducts has been corroborated by an X-ray diffraction study of **4a**, and in the case of **6a** by XH-correlation and HMBC spectra.


**Keywords:** [3+2] dipolar cycloaddition; aryl nitrile oxides; aryl azides; isoxazole; 1,2,3-triazoles

## 1. Introduction

One of the research activities of our laboratory in the domain of heterocyclic chemistry deals with the 1,3-dipolar cycloaddition of nitrile oxides and azides as dipoles across the double or triple bonds of dipolarophiles [1–3]. A very recent example is the 1,3-dipolar cycloaddition of aryl nitrile oxides to the allyl group of ethyl 1-allyl-2-benzyl-3-oxo-2,3-dihydro-1*H*-isoindole-1-carboxylate providing a series of isoxazolines [4]. This versatile strategy for the synthesis of heterocyclic compound is more and more used in materials chemistry, drug discovery, and chemical biology [5–7]. Since the pioneering work of Huisgen, the contributions of Sharpless to “click chemistry” have given an additional impetus for the advancement of cycloaddition reactions [5–15] which are nowadays a trusted tool in targeted synthesis, especially for those involving the construction of heterocyclic systems [6]. The aim of this present work focuses on the synthesis of *N*-heterocyclic compounds, namely the synthesis of substituted isoxazole and triazole derivatives, since an important number of compounds containing the isoxazole and the triazole scaffold are known to exhibit a variety of biological activities in the pharmaceutical [16] and medicinal areas [17]. Representative examples of synthetic drugs incorporating these motifs

are Tazobactam **I** [18–22], Rufinamide **II** [23–25], phenylisoxazole derivatives **III** [26,27], and Bextra (Valdecoxib) **IV** [28–30].

On the other hand, the dihydroisoindolin-1-one ring system is present in numerous synthetic and natural compounds, which exhibit interesting biological properties. For example, 3-substituted dihydroisoindolin-1-ones such as Pazinaclone **V** [31] and Zoplicone **VI** [32–34] possess a pharmaceutical profile similar to that of the benzodiazepines [17] (sedatives, hypnotics) and have been commercialized as anxiolytics (Figure 1). Dihydroisoindolin-1-one derivatives have been extensively studied, but to the best of our knowledge there are no reports on dihydroisoindolin-1-ones incorporating an isoxazole or triazole moiety.



**Figure 1.** Structures of isoxazoles, triazoles and 3-substituted dihydroisoindolin-1-ones exhibiting biological or pharmaceutical activities.


A classical route for the preparation of isoxazole or triazole is the reaction of alkynes with nitrile oxides and aryl azides, respectively [35–37]. In this context and in connection with our current research interest in the preparation of biologically relevant nitrogenated and oxygenated compounds by 1,3-dipolar cycloaddition on unsaturated systems with several 1,3-dipoles [38,39] we wish to describe in this paper an efficient synthesis of a series of novel 3,5-disubstituted isoxazoles and 1,4-disubstituted 1,2,3-triazoles by regioselective reaction of aryl nitrile oxides **1a–d** and azides **2a–d** with the dihydroisoindolin-1-one-derived terminal alkyne **3**. For comparison, we have performed these 1,3-dipolar cycloadditions under non-catalyzed thermal activation in toluene or alternatively in the presence of the simple and inexpensive catalysts CuI and Ag<sub>2</sub>CO<sub>3</sub>. As well established for many other click reactions [40] catalyzed by Cu(I) salts, we obtained the best results using CuI as catalyst.

## 2. Results and Discussion

As previously described by our group [41] the dipolarophile **3** was prepared through an efficient four-step procedure starting from commercially available homophthalic acid, affording the desired bicyclic acetylenic lactam **3** in high yield. We have then examined the 1,3-dipolar cycloaddition reactions of propargyl-substituted dihydroisoindolin-1-one **3** as dipolarophile across aryl nitrile oxides **1a–d** (Ar: a: C<sub>6</sub>H<sub>5</sub>, b: *p*-MeC<sub>6</sub>H<sub>4</sub>, c: *p*-OMeC<sub>6</sub>H<sub>4</sub>, d: *p*-ClC<sub>6</sub>H<sub>4</sub>), generated *in situ* from aromatic oxime precursors [42] and azides [43] **2a–d** (Ar: a: C<sub>6</sub>H<sub>5</sub>, b: *p*-MeC<sub>6</sub>H<sub>4</sub>, c: *p*-MeOC<sub>6</sub>H<sub>4</sub>, d: *p*-ClC<sub>6</sub>H<sub>4</sub>), under conventional conditions (without catalyst) according to Scheme 1.

To find suitable reaction conditions, we conducted first the cycloaddition reaction in various solvents such as dichloromethane, acetonitrile, toluene and DMF both at room temperature and under reflux. Without catalyst, the targeted cycloadducts were only obtained in refluxing toluene,

albeit in moderate amounts. The examination of the TLC of the reactions mixtures indicated the presence of only one product, which, after classical workup, was identified as cycloadducts **4** or **6** resulting from the thermal cycloaddition of the acetylene function and the 1,3-dipoles in accordance with the literature [44–46]. After optimization of the reactions conditions, we then performed all the cycloaddition reactions in presence of  $\text{Ag}_2\text{CO}_3$  (10 mol %) using the same protocol given above.



**Scheme 1.** [3+2] Cycloaddition of dihydroisindolin-1-one **3** with arynitrile oxides **1** and azides **2**.

Table 1 reveals that the silver-catalyzed reaction allowed us to obtain the corresponding isoxazoles **4a–d** and triazoles **6a–d** within a considerably shorter reaction time (24 h) in improved isolated yields (50%–73%) as colorless or yellowish solids. It is worth noting that, as far as we know, this is the first report on an efficient  $\text{Ag}_2\text{CO}_3$ -catalyzed 1,3-dipolar cycloaddition with a propargyl-substituted dihydroisindolin-1-one as dipolarophile. The reaction times could be further shortened to only 6–8 h using 10 mol % of CuI as catalyst. Moreover, all [3+2] cycloadditions involving dipolarophile **3** and arynitrile oxides **1a–d** or azides **2a–d** furnished the desired isoxazoles **4a–d** or triazoles **6a–d** (Ar: a:  $\text{C}_6\text{H}_5$ , b:  $p\text{-MeC}_6\text{H}_4$ , c:  $p\text{-OMeC}_6\text{H}_4$ , d:  $p\text{-ClC}_6\text{H}_4$ ) in even superior yields (63%–89%) compared with the  $\text{Ag}_2\text{CO}_3$ -catalyzed syntheses.


**Table 1.** Formation of isoxazoles **4a–d** and triazoles **6a–d** under conventional and catalytic conditions.

| Products <sup>a</sup> | Conventional Conditions |           | $\text{Ag}_2\text{CO}_3$ -Catalyzed Conditions <sup>b</sup> |           | CuI-Catalyzed Conditions <sup>b</sup> |           |
|-----------------------|-------------------------|-----------|-------------------------------------------------------------|-----------|---------------------------------------|-----------|
|                       | Time (h)                | Yield (%) | Time (h)                                                    | Yield (%) | Time (h)                              | Yield (%) |
| <b>4a</b>             | 48                      | 57        | 24                                                          | 73        | 6                                     | 85        |
| <b>4b</b>             | 120                     | 28        | 24                                                          | 58        | 6                                     | 63        |
| <b>4c</b>             | 48                      | 59        | 24                                                          | 70        | 6                                     | 75        |
| <b>4d</b>             | 72                      | 47        | 24                                                          | 50        | 8                                     | 63        |
| <b>6a</b>             | 48                      | 62        | 24                                                          | 73        | 6                                     | 89        |
| <b>6b</b>             | 72                      | 48        | 24                                                          | 58        | 6                                     | 75        |
| <b>6c</b>             | 48                      | 59        | 24                                                          | 70        | 6                                     | 85        |
| <b>6d</b>             | 48                      | 42        | 24                                                          | 53        | 6                                     | 67        |

<sup>a</sup> all reactions were carried out using toluene at reflux under Argon; <sup>b</sup> the reaction was carried out using 10 mol % of catalyst in presence of  $\text{Et}_3\text{N}$ .

The structures of adduct **4a–d** and **6a–d** were confirmed through X-ray structure elucidation, or by XH correlation and HMBC spectra. It is noteworthy that, independently of the reaction temperature


and catalyst ratio, TLC and NMR analysis indicated that the reaction seems to be highly regioselective. In all the cycloaddition tests, exclusively 3,5-disubstituted isoxazoles **4a–d** and 1,4-disubstituted 1,2,3-triazoles **6a–d** products were obtained (Figure 2).



**Figure 2.** Numbering scheme of the isoxazole **4a–d** and 1,4-disubstituted 1,2,3-triazoles **6a–d**.


### 2.1. Spectroscopic and Crystallographic Characterization of Isoxazole **4a**

The analytical and spectroscopic data are in agreement with the proposed structures illustrated in Scheme 1. The IR spectrum of compound **4a** (Ar = C<sub>6</sub>H<sub>5</sub>) contains an absorption band at  $\nu_{\max} = 1607 \text{ cm}^{-1}$  characteristic of the isoxazole C=N group. The other absorptions at  $\nu_{\max} = 1744$  and  $1717 \text{ cm}^{-1}$  are attributed to the ester C=O and lactam C=O stretching vibrations. The regiochemistry of this adduct was deduced from the <sup>1</sup>H-NMR spectrum, which displays the resonance of the isoxazole proton (4-H) as a singlet at  $\delta = 5.18 \text{ ppm}$ . This value of the chemical shift clearly confirms the regiochemistry of the cycloaddition and is in line with the values reported by Fokin, Sharpless [47–49] and our previous work; *i.e.*, the oxygen atom is bonded to more substituted carbon of an unsymmetrical double or triple bond. In the case of the hypothetical reverse regioisomer **5a**, one should expect a chemical shift value for the 5-H proton higher than 6 ppm due to the proximity of the isoxazolinic oxygen atom [50]. The two diastereotopic 6-H protons appear as two doublets at  $\delta = 3.78$  and  $3.84 \text{ ppm}$  with a <sup>2</sup>*J* coupling constant of 15.3 Hz. No allylic coupling with 4-H was noticed. The second set of doublets at 4.74 (d, 1H, *J* = 15.2 Hz) and 4.85 ppm (d, 1H, *J* = 15.2 Hz) is attributed to the methylenic protons 6'-H, which are non-equivalent due to hindered rotation. Particularly characteristic are the <sup>13</sup>C-NMR isoxazole ring resonances with three peaks at  $\delta = 101.0$ ,  $\delta = 161.9 \text{ ppm}$  and  $\delta = 166.3 \text{ ppm}$  for the isoxazole carbons 4-C, 5-C and 3-C. The carbon 7-C resonates at  $\delta = 70.2 \text{ ppm}$  and the two secondary carbons 6-C and 6'-C are observed at  $\delta = 62.6$  and  $44.9 \text{ ppm}$ , in accordance with the data reported by Fokin and Sharpless [47–49]. A further proof of our structural assignment stems from an X-ray structure determination [50] performed on **4a**, confirming unambiguously the stereochemistry of the product. Two independent molecules are present in the asymmetric unit of the P2<sub>1</sub>/c space group (Figure 3). The intrinsic racemic property of this space group (presence of improper symmetry operations: inversion and reflections) doesn't need the presence of two independent molecules in the asymmetric unit for the overall racemic nature of the crystal. Such a presence of two chiral molecules in the asymmetric unit of the centrosymmetric space group is not a common feature of racemic crystals of chiral molecules. It is rather an indication of the low energy barrier upon S/R isomerization. Such a kind of isomerization in **4a** may occur during the crystallization process, but it may be also expected that both the relative *S* and *R* chiralities centered on the C4 and C34 atoms in two independent molecules should be already present in their solution before crystallization. The metric parameters (bond lengths and angles) observed for both isomers are found in the expected ranges and do not need further comments (Figure 3).



**Figure 3.** Content of the asymmetric unit in the racemic crystal of **4a** ( $P2_1/c$  space group) showing the presence of both *S* (over C34 atom) and *R* (over C4 atom) enantiomers. Hydrogen atoms have been omitted for clarity. Thermal ellipsoids are plotted at 50% probability level. Selected bond lengths (Å) and angles (°): C4–C5 1.541(2), C4–N1 1.469(2), C4–C3 1.556(2), C4–C25 1.521(2), O1–N2 1.416(2), C34–C33 1.558(2), C34–N3 1.465(2), C34–C35 1.521(2), C34–C49 1.538(2), N4–O6 1.416(2); N1–C4–C25 101.4(1), N1–C4–C5 113.4(1), N1–C4–C3 109.1(1), C25–C4–C3 106.7(1), C25–C4–C5 113.7(1), C3–C4–C5 111.9(1), N3–C34–C35 101.5(1), N3–C34–C49 113.6(1), N3–C34–C33 108.9(1), C35–C34–C33 106.5(1), C35–C34–C49 113.9(1), C49–C34–C33 111.8(1).

There is a kind of intermolecular hydrogen bonds in the structure of **4a** consisting of weak C–H···O interactions leading to the formation of 1D arrays running along the *x* direction in the *xz* plane of the crystal lattice. Four associated molecules are shown in Figure 4. The two central ones are present in the asymmetric unit and the two lateral ones stem from the neighboring asymmetric units. The *intra* asymmetric unit (central) O···H–C (O2···C45/C49) distances are 3.253 and 3.302 Å, respectively. The O···H–C (O5···C5/C26) contacts within the *inter*-asymmetric unit (external) fall in the similar range of 3.213 and 3.304 Å.



**Figure 4.** 1D Chain structure of **4a** build through weak O···H–C hydrogen bonds.

## 2.2. Spectroscopic Characterization of Triazole 6a

The IR spectrum of **6a** shows C=O absorptions bands at 1738 and 1701  $\text{cm}^{-1}$  due to the ester and lactam carbonyls. The combination of  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectroscopy allows one to deduce in an unambiguously manner the exclusive formation of triazolic regioisomers **6** as exemplified for **6a**. The characteristic signal of triazole proton 5-H appears as a singlet at  $\delta = 6.34$  ppm. Moreover, the presence of the  $^2J$  coupling constant of 15.2 Hz between the two diastereotopic protons 6-H at  $\delta = 3.66$ – $3.76$  and  $3.85$ – $3.96$  ppm on the one hand and the non-equivalent methylene protons 6'-H at  $\delta = 4.75$  and  $4.90$  ppm on the other hand as observed in the case of the cycloaddition of propargyl-substituted dihydroisindolin-1-one **3** with aryl nitrile oxides **1a–d** corroborating the structural assignment. An additional proof concerning the regiochemistry of the copper-catalyzed [3+2] cycloaddition reaction is provided by the  $^{13}\text{C}$ -NMR data. The chemical shifts of the carbon atom 5-C at  $\delta = 120.0$  ppm and that of carbon 4-C at  $\delta = 143.8$  ppm are characteristic for 1,4-disubstituted-1H-1,2,3-triazoles [47–51]. The C atom 4-C of the hypothetical isomeric compound **7a** should appear at around 133 ppm [51]. Formation of these regioisomeric 1,5-disubstituted-1H-1,2,3-triazoles has been reported to occur by Ru-catalyzed cycloaddition [52,53], but we are not aware of copper-catalyzed reactions leading to these isomers. The carbon 7-C resonates at  $\delta = 71.5$  ppm, and the secondary carbon 6'-Cat  $\delta = 62.7$  ppm is downfield-shifted due to of deshielding effect of the nitrogen atom. The XH correlation spectrum of **6a** reveals a  $^1J$  correlation between the carbon 5-C and the 5-H proton, characteristic of a triazole cycle. The structural assignment of **6a** was furthermore confirmed by the analysis of its HMBC spectrum, where a  $^2J$  correlation between the proton 5-H and its adjacent carbon 4-C has been established (Figures 5 and 6). The similarity of the spectroscopic data of derivatives **6b**, **6c** and  $\mathbf{6d}$  with those of **6a** allows to conclude that all compounds of series **6** are isostructural, regardless of the electron-withdrawing or electron-donating propensity of the substituent at the *para*-position of the aryl group of azides **2a–d**.




Figure 5. HMBC correlation spectrum of **6a**.




Figure 6. XH correlation spectrum of 6a.

### 3. Experimental Section

#### 3.1. General Information

Reactions were carried out under an atmosphere of dry  $N_2$ . Solvents were purified by standard methods and freshly distilled under nitrogen and dried before use, toluene was distilled under sodium. All melting points were measured on a Kofler bank. The IR infrared spectra were recorded spectra from KBr on a FT-IR Paragon 1000 IR spectrometer (Perkin-Elmer, Akron, Ohio, OH, USA) and only structurally significant bands are reported. Materials: solid thin-layer chromatography (TLC); TLC plates (silica gel 60 F<sub>254</sub> 0.2 mm 20 cm × 20 cm or with aluminum plates (0.20 mm) precoated with fluorescent silica gel, Merck); substances were detected using UV light at 254 nm. TLC was performed using EtOAc/cyclohexane as eluent. Reaction components were then visualized under UV light and dipped in iodine or a Dragendorff solution. All reactions were performed under an inert atmosphere. NMR spectra were recorded with a Bruker AC 300 spectrometer (Bruker Spectrospin, Rheinstetten, Germany) operating at 300 MHz for  $^1H$  and 75.5 MHz for  $^{13}C$  using TMS as the internal standard (0.00 ppm) in  $CDCl_3$  as solvent. Chemical shifts were reported in ppm downfield from TMS.

#### 3.2. Typical Procedure of the Cycloaddition Reaction of Arylnitrile Oxides **1a–d** and Ethyl-3-alkyldiynyl-phthalimidine-3-carboxylate (**3**)

To a mixture of dipolarophile **3** (0.9 mmol) and aryl nitrile oxides precursors **1a–d** (0.9 mmol) in 10 mL of degassed toluene was added triethylamine (0.9 mmol) and CuI or  $Ag_2CO_3$  (10 mol %). The reaction mixture was refluxed for 6–8 h. After filtration of triethylamine hydrochloride, the filtrate was concentrated under reduced pressure. The corresponding cycloadducts was obtained by crystallization in a minimum of EtOH.

*Ethyl 2-benzyl-3-oxo-1-((3-phenyl)isoxazol-5-yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylate (4a)*. Yield 85%; colorless solid; mp 147–149 °C; IR ( $\nu$ ,  $cm^{-1}$  KBr) 3031, 1744, 1717, 1607, 1236;  $^1H$ -NMR:  $\delta$  0.97 (t, 3H,  $J = 7.1$  Hz), 3.68–3.75 (d, 1H,  $J = 15.3$  Hz), 3.84 (q, 2H,  $J = 7.1$  Hz), 3.87–3.97 (d, 1H,  $J = 15.3$  Hz), 4.74 (d, 1H,  $J = 15.2$  Hz), 4.85 (d, 1H,  $J = 15.2$  Hz), 5.18 (s, 1H), 7.24–7.84 (m, aromatic H) ppm;  $^{13}C$ -NMR:  $\delta$

13.6 (CH<sub>3</sub>), 30.7 (CH<sub>2</sub>), 44.9 (CH<sub>2</sub>), 62.6 (CH<sub>2</sub>), 70.6 (Cq), 101.0 (CH<sub>isox</sub>), 121.7 (CH), 124.2 (CH), 126.6 (2CH), 127.8 (CH), 128.6 (CH), 128.7 (2CH), 129.1 (2CH), 129.7 (CH), 129.9 (CH), 131.4 (CH), 132.4 (CH), 136.9 (CH), 142.9 (CH), 161.9 (C<sub>isox</sub>), 166.3 (C<sub>isox</sub>), 169.2 (CO), 169.5 (CO). Anal. Calcd for C<sub>28</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub> (452.17): C, 74.32; H, 5.35; N, 6.19. Found: C, 74.50; H, 5.20; N, 6.10.

*Ethyl 2-Benzyl-3-oxo-1-((3-(4-methylphenyl)isoxazol-5-yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylate (4b)*. Yield 63%; colorless solid; mp 115–117 °C; IR (ν, cm<sup>−1</sup> KBr) 3034, 1733, 1717, 1700, 1257; <sup>1</sup>H-NMR: δ 0.99 (t, 3H, J = 7.2 Hz), 2.36 (s, 3H), 3.70–3.80 (d, 1H, J = 15.3 Hz), 3.86 (q, 2H, J = 7.2 Hz), 3.91–3.99 (d, 1H, J = 15.3 Hz), 4.76 (d, 1H, J = 15.2 Hz), 4.86 (d, 1H, J = 15.2 Hz), 5.28 (s, 1H), 7.17–7.86 (m, aromatic H) ppm; <sup>13</sup>C-NMR: δ 13.9 (CH<sub>3</sub>), 21.7 (CH<sub>3</sub>), 31.1 (CH<sub>2</sub>), 45.2 (CH<sub>2</sub>), 62.9 (CH<sub>2</sub>), 70.6 (Cq), 101.2 (CH<sub>isox</sub>), 122.0 (CH), 124.5 (CH), 126.2 (CH), 126.8 (2CH), 128.1 (CH), 128.9 (2CH), 129.5 (2CH), 130.0 (CH), 131.8 (CH), 132.7 (CH), 137.2 (CH), 140.3 (CH), 143.3 (CH), 162.3 (C<sub>isox</sub>), 166.5 (C<sub>isox</sub>), 169.6 (CO), 169.8 (CO). Anal. Calcd for C<sub>29</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> (466.20): C, 74.66; H, 5.62; N, 6.00. Found: C, 74.82; H, 5.74; N, 5.94

*Ethyl 2-Benzyl-3-oxo-1-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylate (4c)*. Yield 75%; yellow solid; mp 169–171 °C; IR (ν, cm<sup>−1</sup> KBr) 3030, 1734, 1692, 1611, 1250; <sup>1</sup>H-NMR: δ 0.98 (t, 3H, J = 7.1 Hz), 3.64–3.75 (d, 1H, J = 15.3 Hz), 3.80 (s, 3H), 3.84 (q, 2H, J = 7.1 Hz), 3.85–3.90 (d, 1H, J = 15.3 Hz), 3.92–3.98 (d, 1H, J = 15.2 Hz), 4.71–4.87 (d, 1H, J = 15.2 Hz), 5.18 (s, 1H); 7.27–7.86 (m, aromatic H) ppm; <sup>13</sup>C-NMR: δ 13.6 (CH<sub>3</sub>), 30.7 (CH<sub>2</sub>), 44.8 (CH<sub>2</sub>), 62.6 (CH<sub>2</sub>), 70.2 (Cq), 100.8 (CH<sub>isox</sub>), 121.6 (CH), 124.1 (CH), 127.1 (CH), 127.7 (CH), 127.8 (2CH), 128.5 (2CH), 128.9 (2CH), 129.1 (2CH), 129.7 (CH), 131.3 (CH), 132.4 (CH), 135.8 (CH), 136.8 (CH), 142.8 (CH), 160.9 (C<sub>isox</sub>), 166.6 (C<sub>isox</sub>), 169.2 (CO), 169.4 (CO). Anal. Calcd for C<sub>29</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub> (482.18): C, 72.18; H, 5.43; N, 5.81. Found: C, 72.08; H, 5.35; N, 5.72.

*Ethyl 2-Benzyl-3-oxo-1-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylate (4d)*. Yield 67%; colorless solid; mp 134–136 °C; IR (ν, cm<sup>−1</sup> KBr) 3066, 1734, 1695, 1610, 1263; <sup>1</sup>H-NMR: δ 0.98 (t, 3H, J = 7.1 Hz), 3.70–3.79 (d, 1H, J = 15.3 Hz), 3.84 (q, 2H, J = 7.1 Hz), 3.92–3.96 (d, 1H, J = 15.3 Hz), 4.71 (d, 1H, J = 15.1 Hz), 4.87 (d, 1H, J = 15.1 Hz), 5.18 (s, 1H), 7.27–7.86 (m, aromatic H) ppm; <sup>13</sup>C-NMR: δ 13.6 (CH<sub>3</sub>), 30.7 (CH<sub>2</sub>), 44.8 (CH<sub>2</sub>), 62.6 (CH<sub>2</sub>), 70.2 (Cq), 100.8 (CH<sub>isox</sub>), 121.6 (CH), 124.1 (CH), 127.1 (CH), 127.7 (CH), 127.8 (2CH), 128.5 (2CH), 128.9 (2CH), 129.1 (2CH), 129.7 (CH), 131.3 (CH), 132.4 (CH), 135.8 (CH), 136.8 (CH), 142.8 (CH), 160.9 (C<sub>isox</sub>), 166.6 (C<sub>isox</sub>), 169.2 (CO), 169.4 (CO). Anal. Calcd for C<sub>28</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>4</sub> (486.13): C, 69.06; H, 4.76; Cl, 7.28; N, 5.75. Found: C, 68.98; H, 4.94; Cl, 7.32; N, 5.57.

### 3.3. Typical Procedure of the Cycloaddition Reaction of Azides **2a–d** and Ethyl 3-Alkylidynylphthalimidine-3-carboxylate (**3**)

A mixture of dipolarophile **3** (0.9 mmol), azides **2a–d** (0.9 mmol) and CuI or Ag<sub>2</sub>CO<sub>3</sub> (10 mol %) in dry toluene (10 mL) was stirred under argon atmosphere at 110 °C. after the completion of the reaction indicated by TLC analysis, solvent was evaporated under reduced pressure and the crude mixture was purified by crystallization in a minimum of EtOH solution.

*Ethyl 2-Benzyl-3-oxo-1-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylate (6a)*. Yield 89%; yellow solid; mp 145–147 °C; IR (ν, cm<sup>−1</sup> KBr) 3036, 1738, 1701, 1242; <sup>1</sup>H-NMR: δ 0.97 (t, 3H, J = 7.1 Hz), 3.66–3.76 (d, 1H, J = 15.2 Hz), 3.85–3.96 (d, 1H, J = 15.2 Hz), 3.91 (q, 2H, J = 7.1 Hz), 4.75 (d, 1H, J = 15.4 Hz), 4.90 (d, 1H, J = 15.4 Hz), 6.34 (s, 1H<sub>triaz</sub>), 7.22–7.77 (m, aromatic H) ppm; <sup>13</sup>C-NMR: δ 14.0 (CH<sub>3</sub>), 30.2 (CH<sub>2</sub>), 45.4 (CH<sub>2</sub>), 62.7 (CH<sub>2</sub>), 71.5 (C<sub>q</sub>), 120.0 (CH<sub>triaz</sub>), 120.5 (2CH), 122.4 (CH), 124.2 (CH), 128.0 (CH), 128.9 (CH), 129.7 (2CH), 129.8 (CH), 129.9 (2CH), 131.9 (CH), 132.6 (CH), 137.0 (CH), 141.3 (CH), 143.8 (C<sub>triaz</sub>), 169.8 (CO), 170.2 (CO). Anal. Calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub> (452.18): C, 71.67; H, 5.35; N, 12.38. Found: C, 71.80; H, 5.42; N, 12.42.

*Ethyl 2-Benzyl-3-oxo-1-((1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylate (6b)*. Yield 75%; colorless solid; mp 146–148 °C; IR (ν, cm<sup>−1</sup> KBr) 3035, 1735, 1701, 1246; <sup>1</sup>H-NMR: δ 0.90 (t, 3H, J = 7.1 Hz), 2.29 (s, 3H), 3.61–3.64 (d, 1H, J = 15.2 Hz), 3.83 (q, 2H, J = 7.1 Hz), 3.80–3.82 (d,

1H,  $J = 15.2$  Hz), 4.69 (d, 1H,  $J = 15.4$  Hz), 4.82 (d, 1H,  $J = 15.4$  Hz), 6.24 (s, 1H), 7.10–7.71 (m, aromatic H) ppm;  $^{13}\text{C}$ -NMR:  $\delta$  12.5 ( $\text{CH}_3$ ), 20.0 ( $\text{CH}_3$ ), 28.8 ( $\text{CH}_2$ ), 44.0 ( $\text{CH}_2$ ), 61.3 ( $\text{CH}_2$ ), 70.0 ( $\text{C}_q$ ), 118.6 ( $\text{CH}_{\text{triaz}}$ ), 119.0 (2CH), 121.0 (CH), 122.8 (CH), 126.6 (CH), 127.5 (2CH), 128.2 (2CH), 128.3 (CH), 128.9 (2CH), 130.5 (CH), 131.2 (CH), 133.3 (CH), 136.3 (CH), 137.5 (CH), 139.7 (CH), 142.4 ( $\text{C}_{\text{triaz}}$ ), 168.3 (CO), 168.8 (CO). Anal. Calcd for  $\text{C}_{28}\text{H}_{26}\text{N}_4\text{O}_3$  (466.20): C, 72.09; H, 5.62; N, 12.01. Found: C, 71.98; H, 5.80; N, 12.09.

*Ethyl 2-Benzyl-3-oxo-1-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3-dihydro-1H-isoindeole-1-carboxylate* (**6c**). Yield 85%; pink solid; mp 165–167 °C; IR ( $\nu$ ,  $\text{cm}^{-1}$  KBr) 3033, 1735, 1690, 1254;  $^1\text{H}$ -NMR:  $\delta$  0.89 (t, 3H,  $J = 7.1$  Hz), 3.74 (s, 3H), 3.77–3.82 (d, 1H,  $J = 15.1$  Hz), 3.83 (q, 2H,  $J = 7.1$  Hz), 4.80 (d, 1H,  $J = 15.1$  Hz), 4.85 (d, 1H,  $J = 15.4$  Hz), 4.92 (d, 1H,  $J = 15.4$  Hz), 6.20 (s, 1H), 6.80–7.71 (m, aromatic H) ppm;  $^{13}\text{C}$ -NMR:  $\delta$  12.5 ( $\text{CH}_3$ ), 28.8 ( $\text{CH}_2$ ), 44.0 ( $\text{CH}_2$ ), 54.5 ( $\text{CH}_3$ ), 61.3 ( $\text{CH}_2$ ), 70.0 ( $\text{C}_q$ ), 113.4 (2CH), 118.7 ( $\text{CH}_{\text{triaz}}$ ), 120.7 (2CH), 121.0 (CH), 122.8 (CH), 126.5 (CH), 127.5 (2CH), 128.2 (2CH), 128.3 (CH), 129.0 (CH), 130.5 (CH), 131.2 (CH), 136.3 (CH), 139.6 (CH), 142.4 ( $\text{C}_{\text{triaz}}$ ), 168.3 (CO), 168.8 (CO). Anal. Calcd for  $\text{C}_{28}\text{H}_{26}\text{N}_4\text{O}_4$  (482.20): C, 69.70; H, 5.43; N, 11.61. Found: C, 69.85; H, 5.37; N, 11.57.

*Ethyl 2-Benzyl-3-oxo-1-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3-dihydro-1H-isoindeole-1-carboxylate* (**6d**). Yield 67%; colorless solid; mp 154–156 °C; IR ( $\nu$ ,  $\text{cm}^{-1}$  KBr) 3056, 1725, 1697, 1245;  $^1\text{H}$ -NMR:  $\delta$  0.93 (t, 3H,  $J = 7.1$  Hz), 3.66–3.68 (d, 1H,  $J = 15.2$  Hz), 3.83 (q, 2H,  $J = 7.1$  Hz), 3.90 (d, 1H,  $J = 15.2$  Hz), 4.63 (d, 1H,  $J = 15.2$  Hz), 4.86 (d, 1H,  $J = 15.2$  Hz), 6.18 (s, 1H), 7.19–7.70 (m, aromatic H) ppm;  $^{13}\text{C}$ -NMR:  $\delta$  12.6 ( $\text{CH}_3$ ), 28.7 ( $\text{CH}_2$ ), 44.1 ( $\text{CH}_2$ ), 61.4 ( $\text{CH}_2$ ), 70.1 ( $\text{C}_q$ ), 118.6 ( $\text{CH}_{\text{triaz}}$ ), 120.2 (2CH), 121.0 (CH), 122.8 (CH), 126.6 (CH), 127.5 (2CH), 128.3 (2CH), 128.4 (CH), 128.6 (2CH), 130.4 ( $\text{C}_q$ ), 131.3 (CH), 133.1 (CH), 134.0 (CH), 136.4 (CH), 140.1 (CH), 142.3 ( $\text{C}_{\text{triaz}}$ ), 168.4 (CO), 168.8 (CO). Anal. Calcd for  $\text{C}_{27}\text{H}_{23}\text{ClN}_4\text{O}_3$  (486.15): C, 66.60; H, 4.76; Cl, 7.28; N, 11.51. Found: C, 66.83; H, 4.68; Cl, 7.20; N, 11.70.

### 3.4. X-ray Diffraction Structure Analysis of **4a**

A colorless crystal of **4a** has been mounted on a Apex II diffractometer (Bruker Nonius Kappa, Karlsruhe, Germany) and the intensity data have been collected at 115 K with Mo  $\text{K}\alpha$  radiation of  $\lambda = 0.71073$  Å. These data were further treated with Denzo and Scalpack programs [54]. The model of the structure has been solved by direct methods with SIR92 [55] and refined with SHELXL-97 [56]. All non-hydrogen atoms were refined with anisotropic temperature factors. All H atoms were placed in calculated positions and refined as riding on the heavy atoms bearing them. The resolution of the structure revealed the presence of two enantiomer molecules in the asymmetric unit of  $\text{P}2_1/\text{c}$  space group.

Crystallographic data have been deposited with the Cambridge Crystallographic Data Center: deposition number CCDC 1405500 contains detailed crystallographic data for this publication. These data may be obtained free of charge from the Cambridge Crystallographic Data Center through [www.ccdc.cam.ac.uk/data\\_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif).

## 4. Conclusions

We have developed a new and efficient method for the synthesis of novel isoxazole and 1,2,3-triazole-substituted dihydroisindolin-1-ones. The process involves regiospecific [3+2] cycloaddition between a propargylic alkyne and aryl nitrile oxides or azides using  $\text{Ag}_2\text{CO}_3$  or CuI as simple commercially available catalysts in toluene at 110 °C. The electron-withdrawing or electron-donating propensity of the substituent at the *para*-position of the aryl group of aryl nitrile oxides **1** or azides **2** have no impact on the outcome of the reaction; future studies will show whether a substitution at the *ortho*-position may influence the stereochemistry of these cycloaddition across the acetylenic dipolarophile **3**. The biological activity and inhibitory effect of such analogues is under examination, as well as applications in analogous natural product syntheses.

**Acknowledgments:** M.K., K.C. and M.M.K. thank the CNRS for financial support.

**Author Contributions:** M.M.R., W.G. and H.M. conceived and performed the experiments; M.E.B.R., K.C. and M.K. wrote the paper. Y.R. and M.M.K. performed the crystallographic work. All authors read and approved the final manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References and Notes

1. Wannassi, N.; Rammah, M.M.; Boudriga, S.; Rammah, M.B.; Monnier-Jobé, K.; Ciamala, K.; Knorr, M.; Enescu, M.; Rousselin, Y.; Kubicki, M.M. Regio- and Stereoselective 1,3-Dipolar Cycloaddition of C-Aryl-N-phenylnitrones over (E)-Arylidene-(2H)-indan-1-ones: Synthesis of Highly Substituted Novel Spiro-isoxazolidines. *Heterocycles* **2010**, *81*, 2749–2762.
2. Boudriga, S.; Wannassi, N.; Askri, M.; Rammah, M.E.B.; Strohmman, C. Diastereoselective synthesis and structure of spiroisoxazoline derivatives. *J. Soc. Chim. Tunisie* **2009**, *11*, 29–36.
3. Askri, M.; Rammah, M.; Monnier-Jobé, K.; Ciamala, K.; Knorr, M.; Strohmman, C. Synthesis of Some Spirochroman-4-Ones by Regioselective [4+2] Cycloaddition Reactions. *Lett. Org. Chem.* **2007**, *4*, 221–227. [[CrossRef](#)]
4. Laouiti, A.; Rammah, M.; Askri, M.; Rammah, M.E.B. 1,3-dipolar cycloaddition of aryl nitrile oxides with ethyl 1-allyl-2-benzyl-3-oxo-2,3-dihydro-1H-isoinole-1-carboxylates. *J. Soc. Chim. Tunis.* **2014**, *16*, 83–88.
5. Padwa, A.; Pearson, W.H. *Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products*; John Wiley and Sons: New York, NY, USA, 2003; Volume 59, pp. 1–940.
6. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. *Angew. Chem. Int. Ed.* **2001**, *40*, 2004–2021. [[CrossRef](#)]
7. Padwa, A.; Huisgen, R. *1,3-Dipolar Cycloaddition Chemistry*; John Wiley & Sons: New York, NY, USA, 1984; Volume 1.
8. Huisgen, R.; Seidel, M.; Wallbilich, G.; Knapfer, H. Diphenylnitrilimine and its 1,3-dipolar additions to alkenes and alkynes. *Tetrahedron Lett.* **1962**, *17*, 3–29. [[CrossRef](#)]
9. Huisgen, R. 1,3-Dipolar Cycloadditions. Past and Future. *Angew. Chem. Int. Ed. Engl.* **1963**, *2*, 565–598. [[CrossRef](#)]
10. Huisgen, R. Neues über 1,3-Cycloadditionen. *Helv. Chim. Acta* **1967**, *50*, 2421–2439. [[CrossRef](#)]
11. Huisgen, R.; Knapfer, H.; Sustmann, R.; Wallbilich, G. 1,3-Dipolare Cycloadditionen. Zur Anlagerung des Diphenylnitrilimins an nichtkonjugierte Alkene und Alkine; Sterischer Ablauf, Orientierung und Substituenteneinfluss. *Chem. Ber.* **1967**, *100*, 1580–1592. [[CrossRef](#)]
12. Huisgen, R.; Knapfer, H.; Sustmann, R.; Wallbilich, G.; Clovis, J.S.; Eckel, A. 1,3-Dipolare Cycloadditionen. Diphenylnitrilimin und arylkonjugierte Alkene. *Chem. Ber.* **1967**, *100*, 1593–1601.
13. Padwa, A. *Comprehensive Organic Synthesis*; Trost, B.M., Fleming, I., Eds.; Pergamon: Oxford, UK, 1991; Volume 4, p. 1069.
14. Gothelf, K.V.; Jørgensen, K.A. Asymmetric 1,3-Dipolar Cycloaddition Reactions. *Chem. Rev.* **1998**, *98*, 863–909. [[CrossRef](#)] [[PubMed](#)]
15. Padwa, A.; Weingarten, M.D. Cascade Processes of Metallo Carbenoids. *Chem. Rev.* **1996**, *96*, 223–270. [[CrossRef](#)] [[PubMed](#)]
16. Hauck, S.I.; Cederberg, C.; Doucette, A.; Grosser, L.; Hales, N.J.; Poon, G.; Gravestock, M.B. New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 337–340. [[CrossRef](#)] [[PubMed](#)]
17. Malawska, B. New anticonvulsant agents. *Curr. Top. Med. Chem.* **2005**, *5*, 69–85. [[CrossRef](#)] [[PubMed](#)]
18. Holla, B.S.; Mahalinga, M.; Karthikeyan, M.S.; Poojary, B.; Akberali, P.M.; Kumari, N.S. Synthesis, characterization and antimicrobial activity of some substituted 1,2,3-triazoles. *Eur. J. Med. Chem.* **2005**, *40*, 1173–1178. [[CrossRef](#)] [[PubMed](#)]
19. Upadhyaya, R.S.; Kulkarni, G.M.; Vasireddy, N.R.; Dixit, S.S.; Sharma, V.; Chattopadhyaya, J. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against *Mycobacterium tuberculosis*. *Bioorg. Med. Chem.* **2009**, *17*, 4681–4692. [[CrossRef](#)] [[PubMed](#)]
20. Gill, C.; Gadhav, G.; Shaikh, M.; Kale, R. Clubbed [1,2,3] triazoles by fluorine benzimidazole: A novel approach to H37Rv inhibitors as a potential treatment for tuberculosis. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 6244–6247. [[CrossRef](#)] [[PubMed](#)]

21. Banday, A.H.; Shameem, S.A.; Ganai, B.A. Antimicrobial studies of unsymmetrical bis-1,2,3-triazoles. *Org. Med. Chem. Lett.* **2012**, *2*, 13–19. [[CrossRef](#)] [[PubMed](#)]
22. Jordao, A.K.; Afonso, P.P.; Ferreira, V.F.; de Souza, M.C.; Almeida, C.O.; Beltrame, C.O.; Paiva, D.P.; Wardell, S.M.; Wardell, J.L.; Tiekink, E.R.; *et al.* Antiviral evaluation of *N*-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture. *Eur. J. Med. Chem.* **2009**, *44*, 3777–3783. [[CrossRef](#)] [[PubMed](#)]
23. Attolino, E.; Colombo, L.; Mormino, I.; Allegrini, P. Method for the Preparation of Rufinamide Using 1,3-Dipolar Cycloaddition as the Key Step. EP Patent 230.234 A1, 22 September 2010.
24. Bonacorso, H.G.; Maraes, M.C.; Luz, F.M.; Quintana, P.S.; Zarrata, N.; Martins, M.A.P. New solventless and metal-free synthesis of the antiepileptic drug 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide) and analogues. *Tetrahedron Lett.* **2015**, *56*, 441–444. [[CrossRef](#)]
25. Perisic-Janjic, N.; Kaliszan, R. Reversed-Phase TLC and HPLC Retention Data in Correlation Studies with in Silico Molecular Descriptors and Druglikeness Properties of Newly Synthesized Anticonvulsant Succinimide Derivatives. *J. Am. Chem. Soc.* **2011**, *8*, 555–563. [[CrossRef](#)] [[PubMed](#)]
26. Gupta, G.; Jain, R.K.; Maikhuri, J.P.; Shukla, P.K.; Kumar, M.; Roy, A.K.; Patra, A.; Singh, V.; Batra, S. Discovery of substituted isoxazolecarbaldehydes as potent spermicides, acrosin inhibitors and mild anti-fungal agents. *Hum. Reprod.* **2005**, *20*, 2301–2308. [[CrossRef](#)] [[PubMed](#)]
27. Juntao, Z.; Wei, T.; Jingjing, Q.; Diya, L.; Yang, L.; Yan, J.; Guoqiang, D.; Qianqian, C.; Youjun, Z.; Ju, Z.; *et al.* Design and synthesis of phenylisoxazole derivatives as novel human acrosin inhibitors. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 2802–2806.
28. Talley, J.J.; Bertenshaw, S.R.; Brown, D.L.; Carter, J.S.; Graneto, M.J.; Kellog, M.S.; Koboldt, C.M.; Yuan, J.; Zhang, Y.Y.; Seibert, K. *N*-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration. *J. Med. Chem.* **2000**, *43*, 1661–1663. [[CrossRef](#)] [[PubMed](#)]
29. Toyokuni, T.; Dileep, J.S.; Walsh, J.C.; Shapiro, A.; Talley, J.J.; Phelps, M.E.; Herschman, H.R.; Barrio, J.R.; Satyamurthy, N. Synthesis of 4-(5-[<sup>18</sup>F]fluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide, a new [<sup>18</sup>F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4699–4702. [[CrossRef](#)] [[PubMed](#)]
30. Penning, T.D.; Talley, J.J.; Berterishaw, S.R.; Carter, J.S.; Collins, P.W.; Docter, S.; Graneto, M.J.; Lee, L.F.; Malecha, J.W.; Miyashiro, J.M.; *et al.* Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). *J. Med. Chem.* **1997**, *40*, 1347–1365. [[CrossRef](#)] [[PubMed](#)]
31. Takahashi, I.; Kawakami, T.; Hirano, E.; Yokota, H.; Kitajima, H. Novel Phthalimidine Synthesis. Mannich Condensation of *o*-Phthalaldehyde with Primary Amines using 1,2,3-1*H*-Benzotriazole and 2-Mercaptoethanol as Dual Synthetic Auxiliaries. *Synlett* **1996**, *1996*, 353–355. [[CrossRef](#)]
32. Anzini, M.; Capelli, A.; Vomero, S.; Giorgi, G.; Langer, T.; Bruni, G.; Romero, M.R.; Basile, A.S. Molecular Basis of Peripheral vs Central Benzodiazepine Receptor Selectivity in a New Class of Peripheral Benzodiazepine Receptor Ligands Related to Alpidem. *J. Med. Chem.* **1996**, *39*, 4275–4284. [[CrossRef](#)] [[PubMed](#)]
33. Gotor, V.; Limeres, F.; Garcia, R.; Bayod, M.; Brieva, R. Enzymatic resolution of (±)-6-(5-chloropyridin-2-yl)-6-vinyloxy-carbonyloxy-6,7-dihydro[5*H*]pyrrolo[3,4-*b*]pyrazin-5-one. Synthesis of (+)-zopiclone. *Tetrahedron Asymmetry* **1997**, *8*, 995–997. [[CrossRef](#)]
34. Goa, K.; Heel, R.C. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as a hypnotic. *Drugs* **1986**, *32*, 48–65. [[CrossRef](#)] [[PubMed](#)]
35. Da Silva-Alves, D.C.B.; dos Anjos, J.V.; Cavalcante, N.N.M.; Santos, G.K.N.; Navarro, D.A.F.; Srivastava, R.M. Larvicidal isoxazoles: Synthesis and their effective susceptibility towards *Aedes aegypti* larvae. *Bioorg. Med. Chem.* **2013**, *21*, 940–943. [[CrossRef](#)] [[PubMed](#)]
36. McIntosh, M.L.; Naffziger, M.R.; Ashburn, B.O.; Zakharov, L.N.; Carter, R.G. Highly regioselective nitrile oxide dipolar cycloadditions with *ortho*-nitrophenyl alkynes. *Org. Biomol. Chem.* **2012**, *10*, 9204–9213. [[CrossRef](#)] [[PubMed](#)]
37. Mabrou, M.; Bougrin, K.; Benhida, R.; Loupy, A.; Soufiaoui, M. An efficient one-step regiospecific synthesis of novel isoxazolines and isoxazoles of *N*-substituted saccharin derivatives through solvent-free microwave-assisted [3+2] cycloaddition. *Tetrahedron Lett.* **2007**, *48*, 443–447. [[CrossRef](#)]

38. Askri, M.; Ben Hamadi, N.; Msadek, M.; Rammah, M.E.B. Réactivité des énones cycliques vis-à-vis du 2-diazopropane: Synthèse de spiro- $\Delta^3$ -(1,3,4)-oxadiazoline et de pyrazoléine. *J. Soc. Chim. Tunis.* **2006**, *8*, 219–222.
39. Boudriga, S.; Askri, M.; Gharbi, R.; Rammah, M.; Ciamala, K. 1,3-Dipolar Cycloadditions of Arylnitrile oxides and Diarylnitrilimines with some 2-Arylidene-1,3-Indanediones. Regiochemistry of the Reactions. *J. Chem. Res.* **2003**, *2003*, 204–207. [[CrossRef](#)]
40. Kolb, H.C.; Sharpless, K.B. The growing impact of click chemistry on drug discovery. *Drug Discov. Today* **2003**, *8*, 1128–1137. [[CrossRef](#)]
41. Rammah, M.M.; Othman, M.; Ciamala, K.; Strohmman, C.; Rammah, M.B. Silver-catalyzed spirocyclization: First synthesis of spiroisindole- $\gamma$ -methylene- $\gamma$ -butyrolactones. *Tetrahedron* **2008**, *64*, 3505–3516. [[CrossRef](#)]
42. Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V.V.; Noodleman, L.; Sharpless, K.B.; Fokin, L.G. Copper(I)-Catalyzed Synthesis of Azoles. DFT Study Predicts Unprecedented Reactivity and Intermediates. *J. Am. Chem. Soc.* **2005**, *127*, 210–216. [[CrossRef](#)] [[PubMed](#)]
43. Kamalraj, V.R.; Senthil, S.; Kannan, P. One-pot synthesis and the fluorescent behavior of 4-acetyl-5-methyl-1,2,3-triazole regioisomers. *J. Mol. Struct.* **2008**, *892*, 210–215. [[CrossRef](#)]
44. Valizadeh, H.; Amiri, M.; Gholipur, H. Efficient and convenient method for the synthesis of isoxazoles in ionic liquid. *J. Heterocycl. Chem.* **2009**, *46*, 108–110. [[CrossRef](#)]
45. Coutouli-Argyropoulou, E.; Lianis, P.; Mitakou, P.; Giannoulisa, M.A.; Nowak, J. 1,3-Dipolar cycloaddition approach to isoxazole, isoxazoline and isoxazolidine analogues of C-nucleosides related to pseudouridine. *Tetrahedron* **2006**, *62*, 1494–1501. [[CrossRef](#)]
46. Hansen, T.V.; Wu, P.; Fokin, V.V. One-Pot Copper(I)-Catalyzed Synthesis of 3,5-Disubstituted Isoxazoles. *J. Org. Chem.* **2005**, *70*, 7761–7764. [[CrossRef](#)] [[PubMed](#)]
47. Rostovtsev, V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B.A. Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes. *Angew. Chem. Int. Ed.* **2002**, *41*, 2596–2599. [[CrossRef](#)]
48. Zhang, L.; Chen, X.; Xue, P.; Sun, H.H.Y.; Williams, I.D.; Sharpless, K.B.; Fokin, V.V.; Jia, G. Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides. *J. Am. Chem. Soc.* **2005**, *127*, 15998–15999. [[CrossRef](#)] [[PubMed](#)]
49. Lo Vecchio, G.; Garssi, G.; Risitano, F.; Foti, F. Unusual reaction of benzonitrile oxide as phenylnitrosocarbene. *Tetrahedron Lett.* **1973**, *14*, 3777–3780. [[CrossRef](#)]
50. Crystal data for compound **4a** C<sub>28</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub> (115 K): Monoclinic,  $P2_1/c$ ,  $a = 14.149(4)$ ,  $b = 17.091(3)$ ,  $c = 23.576(8)$  Å,  $\beta = 126.741(18)^\circ$ ,  $\lambda = 0.71073$  Å,  $V = 4569(2)$  Å<sup>3</sup>,  $Z = 8$ ,  $D_c = 1.316$  Mg/m<sup>3</sup>.
51. Creary, X.; Anderson, A.; Brophy, C.; Crowell, F.; Funk, Z. Method for Assigning Structure of 1,2,3-Triazoles. *J. Org. Chem.* **2012**, *277*, 8756–8761. [[CrossRef](#)] [[PubMed](#)]
52. Johansson, J.R.; Lincoln, P.; Norden, B.; Kann, N. Sequential One-Pot Ruthenium-Catalyzed Azide-Alkyne Cycloaddition from Primary Alkyl Halides and Sodium Azide. *J. Org. Chem.* **2011**, *76*, 2355–2359. [[CrossRef](#)] [[PubMed](#)]
53. Rasmussen, L.K.; Boren, B.C.; Fokin, V.V. Ruthenium-Catalyzed Cycloaddition of Aryl Azides and Alkynes. *Org. Lett.* **2007**, *9*, 5337–5339. [[CrossRef](#)] [[PubMed](#)]
54. Otwinowski, Z.; Minor, W. Methods in Enzymology. In *Macromolecular Crystallography, Part A*; Carter, C.W., Jr., Sweet, R.M., Eds.; Academic Press: New York, NY, USA, 1997; Volume 276, pp. 307–326.
55. SIR92 Program; Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A. Completion and refinement of crystal structures with SIR92. *J. Appl. Crystallogr.* **1993**, *26*, 343–350.
56. Sheldrick, G.M. A short history of SHELX. *Acta Crystallogr.* **2008**, *A64*, 112–122. [[CrossRef](#)] [[PubMed](#)]

**Sample Availability:** Samples of the compounds not are available from the authors.



© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).